Compositions for use in identification of papillomavirus

Abstract

The present invention relates generally to identification of HPV, and provides methods, compositions and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.

1 . A composition comprising at least one purified oligonucleotide primer pair that comprises forward and reverse primers, wherein said primer pair comprises nucleic acid sequences that are substantially complementary to nucleic acid sequences of two or more different bioagents belonging to the HPV family, wherein said primer pair is configured to produce amplicons comprising different base compositions that correspond to said two or more different bioagents. 
     
     
         2 . The composition of  claim 1 , wherein said primer pair is configured to hybridize with conserved regions of said two or more different bioagents and flank variable regions of said two or more different bioagents. 
     
     
         3 . The composition of  claim 1 , wherein said forward and reverse primers are about 15 to 35 nucleobases in length, and wherein the forward primer comprises at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOS: 1-8, and the reverse primer comprises at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOS: 9-16. 
     
     
         4 . The composition of  claim 1 , wherein said primer pair is selected from the group of primer pair sequences consisting of: SEQ ID NOS: 1:9, 2:10, 3:11, 4:12, 5:13, 6:14, 7:15, and 8:16. 
     
     
         5 . The composition of  claim 1 , wherein said forward and reverse primers are about 15 to 35 nucleobases in length, and wherein: the forward primer comprises at least 70%, sequence identity with the sequence of SEQ ID NO: 1, and the reverse primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 9;
 the forward primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 2, and the reverse primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 10;   the forward primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 3, and the reverse primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 11;   the forward primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 4, and the reverse primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 12;   the forward primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 5, and the reverse primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 13;   the forward primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 6, and the reverse primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 14;   the forward primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 7, and the reverse primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 15; and   the forward primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 8, and the reverse primer comprises at least 70% sequence identity with the sequence of SEQ ID NO: 16.   
     
     
         6 . The composition of  claim 1 , wherein said different base compositions identify said two or more different bioagents at genus, species, or sub-species levels. 
     
     
         7 . The composition of  claim 1 , wherein said two or more amplicons are 45 to 200 nucleobases in length. 
     
     
         8 . A kit comprising the composition of  claim 1 . 
     
     
         9 . The composition of  claim 1 , wherein said different bioagents are selected from the group consisting of HPV-16, HPV-31, HPV-18, HPV-45, HPV-6, and HPV-11. 
     
     
         10 . The composition of  claim 1 , wherein a non-templated T residue on the 5′-end of said forward and/or reverse primer is removed. 
     
     
         11 . The composition of  claim 1 , wherein said forward and/or reverse primer further comprises a non-templated T residue on the 5′-end. 
     
     
         12 . The composition of  claim 1 , wherein said forward and/or reverse primer comprises at least one molecular mass modifying tag. 
     
     
         13 . The composition of  claim 1 , wherein said forward and/or reverse primer comprises at least one modified nucleobase. 
     
     
         14 . The composition of  claim 13 , wherein said modified nucleobase is 5-propynyluracil or 5-propynylcytosine. 
     
     
         15 . The composition of  claim 13 , wherein said modified nucleobase is a mass modified nucleobase. 
     
     
         16 . The composition of  claim 15 , wherein said mass modified nucleobase is 5-Iodo-C. 
     
     
         17 . The composition of  claim 13 , wherein said modified nucleobase is a universal nucleobase. 
     
     
         18 . The composition of  claim 17 , wherein said universal nucleobase is inosine. 
     
     
         19 . A composition comprising an isolated primer 15-35 bases in length selected from the group consisting of SEQ ID NOs 1-16. 
     
     
         20 . A kit, comprising at least one purified oligonucleotide primer pair that comprises forward and reverse primers that are about 20 to 35 nucleobases in length, and wherein said forward primer comprises at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOS: 1-8, and said reverse primer comprises at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOS: 9-16. 
     
     
         21 . A method of determining the presence of a HPV in at least one sample, the method comprising:
 (a) amplifying one or more segments of at least one nucleic acid from said sample using at least one purified oligonucleotide primer pair that comprises forward and reverse primers that are about 20 to 35 nucleobases in length, and wherein said forward primer comprises at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOs: 1-8, and said reverse primer comprises at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOs: 9-16 to produce at least one amplification product; and   (b) detecting said amplification product, thereby determining said presence of said HPV in said sample.   
     
     
         22 . The method of  claim 21 , wherein (a) comprises amplifying said one or more segments of said at least one nucleic acid from at least two samples obtained from different geographical locations to produce at least two amplification products, and (b) comprises detecting said amplification products, thereby tracking an epidemic spread of said HPV. 
     
     
         23 . The method of  claim 21 , wherein (b) comprises determining an amount of said HPV in said sample. 
     
     
         24 . The method of  claim 21 , wherein (b) comprises detecting a molecular mass of said amplification product. 
     
     
         25 . The method of  claim 21 , wherein (b) comprises determining a base composition of said amplification product, wherein said base composition identifies the number of A residues, C residues, T residues, G residues, U residues, analogs thereof and/or mass tag residues thereof in said amplification product, whereby said base composition indicates the presence of HPV in said sample or identifies said HPV in said sample. 
     
     
         26 . The method of  claim 25 , comprising comparing said base composition of said amplification product to calculated or measured base compositions of amplification products of one or more known HPV present in a database with the proviso that sequencing of said amplification product is not used to indicate the presence of or to identify said HPV, wherein a match between said determined base composition and said calculated or measured base composition in said database indicates the presence of or identifies said HPV. 
     
     
         27 . A method of identifying one or more HPV bioagents in a sample, the method comprising:
 (a) amplifying two or more segments of a nucleic acid from said one or more HPV bioagents in said sample with two or more oligonucleotide primer pairs to obtain two or more amplification products;   (b) determining two or more molecular masses and/or base compositions of said two or more amplification products; and   (c) comparing said two or more molecular masses and/or said base compositions of said two or more amplification products with known molecular masses and/or known base compositions of amplification products of known HPV bioagents produced with said two or more primer pairs to identify said one or more HPV bioagents in said sample.   
     
     
         28 . The method of  claim 27 , comprising identifying said one or more HPV bioagents in said sample using three, four, five, six, seven, eight or more primer pairs. 
     
     
         29 . The method of  claim 27 , wherein said one or more HPV bioagents in said sample cannot be identified using a single primer pair of said two or more primer pairs. 
     
     
         30 . The method of  claim 27 , comprising obtaining said two or more molecular masses of said two or more amplification products via mass spectrometry. 
     
     
         31 . The method of  claim 27 , comprising calculating said two or more base compositions from said two or more molecular masses of said two or more amplification products. 
     
     
         32 . The method of  claim 27 , wherein said HPV bioagents are selected from the group consisting of a Papillomaviridae family, a genus thereof; a species thereof, a sub-species thereof, and combinations thereof. 
     
     
         33 . The method of  claim 27 , wherein said two or more primer pairs comprise two or more purified oligonucleotide primer pairs that each comprise forward and reverse primers that are about 20 to 35 nucleobases in length, and wherein said forward primers comprise at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOS: 1-8, and said reverse primers comprise at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID. NOS: 9-16 to obtain an amplification product. 
     
     
         34 . The method of  claim 27 , wherein said primer pairs are selected from the group of primer pair sequences consisting of: SEQ ID NOS: 1:9, 2:10, 3:11, 4:12, 5:13, 6:14, 7:15, and 8:16. 
     
     
         35 . The method of  claim 27 , wherein said determining said two or more molecular masses and/or base compositions is conducted without sequencing said two or more amplification products. 
     
     
         36 . The method of  claim 27 , wherein said one or more HPV bioagents in said sample cannot be identified using a single primer pair of said two or more primer pairs. 
     
     
         37 . The method of  claim 27 , wherein said one or more HPV bioagents in a sample are identified by comparing three or more molecular masses and/or base compositions of three or more amplification products with a database of known molecular masses and/or known base compositions of amplification products of known HPV bioagents produced with said three or more primer pairs. 
     
     
         38 . The method of  claim 27 , wherein said two or more segments of said nucleic acid are amplified from a single gene. 
     
     
         39 . The method of  claim 27 , wherein said two or more segments of said nucleic acid are amplified from different genes. 
     
     
         40 . The method of  claim 27 , wherein members of said primer pairs hybridize to conserved regions of said nucleic acid that flank a variable region. 
     
     
         41 . The method of  claim 40 , wherein said variable region varies between at least two of said HPV bioagents. 
     
     
         42 . The method of  claim 40 , wherein said variable region uniquely varies between at least five of said HPV bioagents. 
     
     
         43 . The method of  claim 27 , wherein said two or more amplification products obtained in (a) comprise major classification and subgroup identifying amplification products. 
     
     
         44 . The method of  claim 43 , comprising comparing said molecular masses and/or said base compositions of said two or more amplification products to calculated or measured molecular masses or base compositions of amplification products of known HPV bioagents in a database comprising genus specific amplification products, species specific amplification products, strain specific amplification products or nucleotide polymorphism specific amplification products produced with said two or more oligonucleotide primer pairs, wherein one or more matches between said two or more amplification products and one or more entries in said database identifies said one or more HPV bioagents, classifies a major classification of said one or more HPV bioagents, and/or differentiates between subgroups of known and unknown HPV bioagents in said sample. 
     
     
         45 . The method of  claim 44 , wherein said major classification of said one or more HPV bioagents comprises a genus or species classification of said one or more HPV bioagents. 
     
     
         46 . The method of  claim 44 , wherein said subgroups of known and unknown HPV bioagents comprise family, strain and nucleotide variations of said one or more HPV bioagents. 
     
     
         47 . A system, comprising:
 (a) a mass spectrometer configured to detect one or more molecular masses of amplicons produced using at least one purified oligonucleotide primer pair that comprises forward and reverse primers, wherein said primer pair comprises nucleic acid sequences that are substantially complementary to nucleic acid sequences of two or more different HPV bioagents; and   (b) a controller operably connected to said mass spectrometer, said controller configured to correlate said molecular masses of said amplicons with one or more HPV bioagent identities.   
     
     
         48 . The system of  claim 47 , wherein said HPV bioagent identities are at genus, species, and/or sub-species levels. 
     
     
         49 . The system of  claim 47 , wherein said forward and reverse primers are about 15 to 35 nucleobases in length, and wherein the forward primer comprises at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOS: 1-8, and the reverse primer comprises at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOS: 9-16. 
     
     
         50 . The system of  claim 47 , wherein said primer pair is selected from the group of primer pair sequences consisting of: SEQ ID NOS: 1:9, 2:10, 3:11, 4:12, 5:13, 6:14, 7:15, and 8:16. 
     
     
         51 . The system of  claim 47 , wherein said controller is configured to determine base compositions of said amplicons from said molecular masses of said amplicons, which base compositions correspond to said one or more HPV bioagent identities. 
     
     
         52 . The system of  claim 47 , wherein said controller comprises or is operably connected to a database of known molecular masses and/or known base compositions of amplicons of known HPV bioagents produced with the primer pair. 
     
     
         53 . A purified oligonucleotide primer pair, comprising a forward primer and a reverse primer that each independently comprise 14 to 40 consecutive nucleobases selected from the primer pair sequences shown in Table 1 and/or Table 2, which primer pair is configured to generate an amplicon between about 50 and 150 consecutive nucleobases in length.